Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
bristol-myers squibb
5
×
life sciences
national blog main
5
×
national top stories
san diego blog main
san diego top stories
san francisco blog main
biotech
boston blog main
boston top stories
clinical trials
new york blog main
new york top stories
san francisco top stories
boulder/denver blog main
boulder/denver top stories
cancer
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
nivolumab
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
cancer immunotherapy
cell therapy
diagnostics
genfit
gilead sciences
immunotherapy
investing
medicare
merck
What
new
5
×
drug
bio
companies
million
nash
raised
roundup
therapeutics
advantages
approval
approved
athena
bar
biogen’s
biopharmaceutical
biotech
biotechs
brings
cancer
ceo
chief
club
continued
convo
countouriotis
crop
data
disease
earlier
exceeded
expect
failures
fatty
financing
firms
gamble
gets
group
haul
Language
unset
Current search:
new
×
" national blog main "
×
" bristol-myers squibb "
×
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
TP Therapeutics Names New CEO, Gets $80M More For Cancer Drug Push
@xconomy.com
5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M